According to Gram Research analysis of a 2026 review in Cell Biology International, celiac disease involves more than genes alone. Epigenetic switches, which turn genes on or off without changing DNA, may link gut bacteria, diet, and infections to immune damage. A strict gluten-free diet remains the proven treatment today.
According to research reviewed by Gram, celiac disease is an autoimmune condition triggered by gluten in people with certain genes. Genes alone do not explain the whole picture, and cases have been rising worldwide. A 2026 review published in Cell Biology International looks at epigenetics, the on-off switches that control how genes behave without changing the DNA code itself. These switches appear to connect gut bacteria, diet, early-life exposures, and infections to immune attacks on the lining of the intestine. The authors also describe two proteins, tissue transglutaminase 2 and interferon-gamma, that may keep the damage going in a repeating cycle. Because these switches may be reversible, the review suggests future treatments could go beyond a gluten-free diet. The paper summarizes existing studies rather than running a new experiment, so these ideas still need testing in people.
Key Statistics
A 2026 review published in Cell Biology International identified four main types of epigenetic changes, including DNA methylation and histone modifications, that may connect genetic risk for celiac disease with environmental triggers.
A 2026 review in Cell Biology International highlighted two proteins, tissue transglutaminase 2 (TG2) and interferon-gamma (IFN-γ), that may form feedback loops that worsen celiac disease, based on a review of existing studies with no new participants.
The Quick Take
- What they studied: How changes in gene activity, gut bacteria, and body chemicals may work together to cause celiac disease, and whether these changes could one day be used as warning signs or treatment targets.
- Who participated: No people took part in this review. The authors gathered and summarized findings from earlier studies, so there was no sample size to report.
- Key finding: The review describes four types of epigenetic changes, including DNA methylation and histone modifications, that may link a person’s genes to outside influences such as diet and gut bacteria. These changes may help explain why celiac disease is rising and why genes alone do not fully predict who gets it.
- What it means for you: If you have celiac disease, a strict gluten-free diet is still the proven treatment. The new ideas in this review are early and mostly point toward future research, so they should not change your current care without talking to your doctor.
The Research Details
This paper is a review article, which means the authors collected and organized findings from many previously published studies on celiac disease. Instead of testing people directly, they looked for patterns across that existing work. Their focus was on epigenetics, a field that studies how genes are switched on or off without changing the underlying DNA sequence.
The authors looked at how these gene switches interact with gut bacteria, which are the microbes living in the digestive system. They also examined how diet, early-life experiences, infections, and some medications might affect these switches. The review pays special attention to how the changes differ between tissues in the body.
Finally, the authors considered whether these switches could be used as biomarkers, which are measurable signs that show what is happening inside the body. They also discussed possible future treatments, such as drugs that adjust gene switches and approaches that change the balance of gut bacteria.
A review is useful for mapping out a topic that has many scattered studies. By pulling these together, the authors can show how different pieces of evidence might fit into one larger picture. This is especially helpful for a complex condition like celiac disease, where genes, bacteria, and environment all seem to play a role.
However, a review cannot prove cause and effect on its own. It can only point out which ideas look promising and which need more testing. Readers should see it as a roadmap for future research rather than a final answer.
This paper appears to be a narrative review in a peer-reviewed journal, which means it has been checked by other experts before publication. Reviews are generally less reliable than large randomized trials because the authors choose which studies to include, and this selection can shape the conclusions. The paper does not report a sample size, so it is not possible to judge the number of people behind the evidence it discusses. The journal’s impact factor was not confirmed for this analysis, so it is not reported here.
What the Results Show
The main message of the review is that celiac disease appears to involve more than inherited genes. People with the HLA-DQ2 or HLA-DQ8 gene types are the most likely to develop the condition, but these genes do not fully explain who gets sick or why cases are increasing around the world. The authors suggest that epigenetic changes may help explain this gap by linking a person’s genetic makeup to outside factors.
The review describes several kinds of epigenetic changes. These include DNA methylation, where small chemical tags are added to DNA; histone modifications, which change how tightly DNA is wrapped; non-coding RNA regulation, where small RNA molecules control gene activity; and RNA methylation, which changes how RNA messages are read. Together, these changes may affect immune responses, the strength of the gut lining, and inflammation.
Gut bacteria and their chemical byproducts, called metabolites, also appear to influence these switches. The authors suggest that this may cause the immune system to lose tolerance to gluten, which then leads to damage in the small intestine. Diet, infections, and early-life exposures may contribute in similar ways.
The review also highlights two key players, tissue transglutaminase 2 (TG2) and interferon-gamma (IFN-γ). According to the authors, these proteins may form feedback loops that keep inflammation and damage going, even when a person is trying to manage the disease.
The authors suggest that some epigenetic changes may be measurable in blood or tissue samples. If confirmed, these changes could serve as biomarkers that help doctors spot celiac disease earlier, track how well it is controlled, or predict who is at higher risk. This idea is still exploratory and has not been validated in large studies within this review.
The review also points out that lifestyle factors and bacterial metabolites can influence epigenetic patterns. Because these influences may be reversible, the authors describe them as possible targets for future interventions, such as diet changes, probiotics, or drugs that modify gene switches. These approaches are discussed as possibilities rather than proven options.
Previous celiac research has focused heavily on genetics and on the immune response to gluten, and the gluten-free diet has long been the standard treatment. This review builds on that work by adding a layer of gene regulation and gut microbiome research. It fits with a growing view in medicine that autoimmune diseases often result from an interaction between genes and environment rather than from genes alone.
Because this is a review, the findings depend on the quality and scope of the studies the authors chose to include. Many of the epigenetic ideas come from small or early-stage research, and some may not hold up in larger studies. The review does not present new experimental data, so it cannot confirm that any specific gene switch causes celiac disease. Most proposed treatments, such as epigenetic drugs and microbiome therapies, have not yet been tested thoroughly in people with celiac disease. Readers should treat the suggestions as hypotheses that need further research.
The Bottom Line
Strict, lifelong avoidance of gluten remains the established treatment for celiac disease, and this review does not change that. Confidence in the gluten-free diet is high because it has been studied for decades. Confidence in the epigenetic and microbiome approaches discussed here is low to moderate, since they are mainly based on early research and proposals. Anyone considering probiotics, supplements, or other products marketed for celiac disease should first discuss them with a doctor or dietitian.
People diagnosed with celiac disease, their family members, and clinicians who manage autoimmune conditions may find this review informative. Researchers looking for new diagnostic markers or treatments may also find it useful. People without celiac disease or gluten-related symptoms do not need to change their diet based on this paper. Anyone with symptoms such as persistent diarrhea, weight loss, or fatigue should speak with a healthcare provider for proper testing before cutting out gluten.
Gluten-free diets can often improve symptoms within a few weeks, and intestinal healing may take several months to a year or more, depending on the person. The newer approaches described in this review are still in early stages, so they are unlikely to become routine care for several years, if they prove useful at all.
Frequently Asked Questions
What causes celiac disease besides genes?
Research reviewed in 2026 suggests that epigenetic changes, which switch genes on or off, may link genetic risk to gut bacteria, diet, infections, and early-life exposures. Genes such as HLA-DQ2 and HLA-DQ8 are necessary for most cases but do not fully explain who develops the condition.
Can gut bacteria affect celiac disease?
A 2026 review suggests that gut bacteria and their chemical byproducts, called metabolites, may influence gene switches that affect immune tolerance to gluten. Researchers view this as a possible future treatment target, but it has not yet been proven in large human studies.
Is there a new treatment for celiac disease beyond a gluten-free diet?
Not yet in routine care. A 2026 review discusses possible approaches such as epigenetic drugs and microbiota-targeted therapies, but these remain experimental. A strict gluten-free diet is still the established treatment for celiac disease.
Can epigenetic changes be used to diagnose celiac disease?
Researchers are exploring whether epigenetic patterns in blood or tissue could serve as biomarkers for celiac disease. A 2026 review describes this as a promising but early idea, and current diagnosis still relies on established blood tests and intestinal biopsies.
Want to Apply This Research?
- Log daily gluten exposure, including any accidental contact, along with symptoms such as bloating, stomach pain, and bowel changes on a 1 to 5 scale. Review the log weekly to spot patterns that may need discussion with a doctor.
- Use the app to check food labels for hidden gluten, save a list of certified gluten-free products, and set reminders to plan meals ahead of time. Logging meals consistently can help identify hidden sources of gluten and support long-term adherence to a gluten-free diet.
- Track symptoms, meals, and any test results or doctor visits over months and years. Share summary reports with your healthcare team at regular checkups. Over time, this record may help you and your doctor see how your body responds to diet changes and whether symptoms are improving as expected.
This article summarizes a review of existing research and does not describe a new clinical trial. The ideas discussed, including epigenetic and microbiome-based approaches, are early-stage and not proven treatments. Celiac disease should be diagnosed and managed by a qualified healthcare provider. Do not start, stop, or change any diet, supplement, or medication based on this article without consulting your doctor or a registered dietitian.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.